Alliancebernstein L.P. Atara Biotherapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.23 - $1.74 $2,185 - $16,530	-9,500 Reduced 5.38%	167,200 $85,000
Q2 2023 Aug 15, 2023	BUY	$1.5 - $3.04 $86,790 - $175,894	57,860 Added 48.69%	176,700 $284,000
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $2,240 - $4,368	-800 Reduced 0.67%	118,840 $344,000
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $35,910 - $65,268	12,600 Added 11.77%	119,640 $392,000
Q3 2022 Nov 15, 2022	BUY	$2.85 - $8.73 $92,340 - $282,852	32,400 Added 43.41%	107,040 $405,000
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $3,752 - $7,872	800 Added 1.08%	74,640 $581,000
Q1 2022 May 13, 2022	BUY	$8.44 - $16.89 $1,688 - $3,378	200 Added 0.27%	73,840 $686,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $24,990 - $33,813	-1,700 Reduced 2.26%	73,640 $1.16 Million
Q3 2021 Nov 10, 2021	SELL	$11.99 - $17.9 $69,542 - $103,819	-5,800 Reduced 7.15%	75,340 $1.35 Million
Q1 2021 May 06, 2021	BUY	$14.0 - $20.72 $33,600 - $49,728	2,400 Added 3.05%	81,140 $1.17 Million
Q3 2020 Nov 12, 2020	BUY	$11.92 - $15.87 $109,664 - $146,004	9,200 Added 13.23%	78,740 $1.02 Million
Q2 2020 Aug 13, 2020	BUY	$7.53 - $14.93 $49,698 - $98,538	6,600 Added 10.49%	69,540 $1.01 Million
Q1 2020 May 14, 2020	BUY	$5.69 - $17.78 $47,227 - $147,574	8,300 Added 15.19%	62,940 $536,000
Q2 2018 Aug 13, 2018	BUY	$35.15 - $51.45 $906,870 - $1.33 Million	25,800 Added 89.46%	54,640 $2.01 Million
Q1 2018 May 14, 2018	BUY	$18.0 - $48.35 $19,800 - $53,185	1,100 Added 3.97%	28,840 $1.13 Million
Q3 2017 Nov 13, 2017	BUY	$13.25 - $17.05 $367,555 - $472,967	27,740	27,740 $459,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account